Can Bestifan (Viliru) be used in combination with other drugs and safety precautions

Belzutifan (Belzutifan) is an oral small molecule HIF-2α inhibitors are mainly used to treat tumors related to the HIF pathway, such as Feng Xibo- Lindau syndrome (VHL)-related renal cell carcinoma. Due to its unique targeting mechanism, researchers and clinicians are gradually exploring the possibility of using it in combination with other anti-cancer drugs to enhance efficacy or delay the occurrence of drug resistance.

In clinical practice and early studies, the combination of besetifan and **immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) ** has shown certain synergistic effects. Mechanistically, HIF-2α inhibition can improve the hypoxic state of the tumor microenvironment, thereby enhancing the ability of immune cells to attack tumors and helping immunotherapy drugs to achieve better results. Some early clinical data suggest that this type of combination regimen can improve response rates in some patients within a tolerable range.

At the same time, bezotivan is also exploring its combination with other targeted drugs or anti-angiogenic drugs. For example, combination with VEGF inhibitors may further inhibit tumor angiogenesis, thereby enhancing anti-tumor effects. However, when using combined drugs, special attention needs to be paid to the problem of superimposed toxicity, such as anemia, fatigue, abnormal blood pressure, etc., which may occur more frequently. Therefore, patients must closely monitor blood routine and blood pressure changes during the combined program under the guidance of a professional doctor.

In general, besetifan can be used in combination with some targeted drugs or immunotherapy, but the combination strategy is still in the exploratory stage and has not yet become a standard treatment option. Safety is the focus of combined medication, and individual adjustments need to be made based on the patient's specific condition, tumor type, and previous medication history. Regular follow-up, monitoring of laboratory indicators and adverse reactions are key measures to ensure efficacy and medication safety.

Reference materials:https://www.drugs.com/